



Prior Authorization- Low Dose Seroquel®

Maricopa County/ Magellan
Updated: 11/3/2011

FDA Approved Formulary Agents:

Quetiapine/XR Seroquel/XR

FDA Approved Indications:

- Schizophrenia, acute
- Schizophrenia, maintenance
- Bipolar Mania, acute (monotherapy or adjunctive)
- Depressive episodes associated with Bipolar Disorder
- Bipolar I disorder, maintenance

Guidelines for approval for quetiapine <150mg/day:

1. FDA approved indication or schizophrenia spectrum disorder (including schizoaffective disorder or schizophreniform disorder).
- AND
2. Inability to tolerate higher doses due to hepatic impairment, CNS sensitivity, or other relevant clinical factors for FDA approved indications.
- OR
3. Children, adolescents, or elderly that require lower doses to avoid side effects (e.g. excessive sedation, cognitive impairment, orthostatic hypertension) for FDA approved indications.
 4. Titrations will be approved for 30 days annually for FDA approved indications.

References:

1. Seroquel ® package insert. AstraZeneca Rev.7/2011. Accessed 10/18/2011.
2. Seroquel XR ® package insert. AstraZeneca Rev. 7/2011. Accessed 10/18/2011.
3. Cohrs, S., Rodenbeck A., et al. Sleep promoting properties of quetiapine in health subjects. *Psychopharmacology* (2004) 174:421-429.
4. Sparshatt, A., Jones, S., Quetiapine: Dose-response relationship in Schizophrenia. *CNS Drugs* (2008) 22(1): 49-48.